Acoramidis Demonstrates Statistically Significant Reduction in Cardiovascular Mortality (CVM) ...

Acoramidis Demonstrates Statistically Significant Reduction in Cardiovascular Mortality (CVM) ...

Acoramidis demonstrated a significant reduction in risk of CVM through 42 months post-randomization, with a 44% hazard reduction, setting a new standard for CVM outcomes for patients with ATTR-CM

Acoramidis Demonstrates Statistically Significant Reduction in Cardiovascular Mortality (CVM) through Month 42 of the ATTRibute-CM Open Label Extension - BridgeBio Pharma (NASDAQ:BBIO)

Acoramidis demonstrated a significant reduction in risk of CVM through 42 months post-randomization, with a 44% hazard reduction, setting a new standard for CVM outcomes for patients with ATTR-CM - Acoramidis also demonstrated a significant 46% hazard reduction in the risk of the composite outcome of CVM or first CVH through 42 months - Acoramidis demonstrated higher rates of disease stabilization or improvement versus disease progression as com…

44% Reduction in Heart Death Risk: BridgeBio's Acoramidis Sets New Standard in ATTR-CM Treatment at 42 Months

BridgeBio's acoramidis demonstrates 44% cardiovascular mortality reduction at 42 months in ATTR-CM patients. Drug shows 46% reduction in composite outcomes and 50% fewer hospitalizations.